semaglutide affect sex drive Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it The Impact of Glucagon-like Peptide-1
Description
If the IMR rules in your favor, Kaiser must provide coverage
Even as levels decline, enough remains in your system to continue producing effects
Why: GLP-1 receptor agonism produces effects across pancreas, brain, heart, kidney, liver, and adipose tissue simultaneously
Risks and concerns warrant careful consideration
